Rheumatoid arthritis

Rheumatoid interstitial lung disease in Canterbury, Aotearoa New Zealand – A retrospective cohort study

Semin Arthritis RheumPublished Retrospective cohort study

Authors' conclusion

Clinically evident RA-ILD occurred in approximately 5 % of individuals with RA. Mortality was increased almost fourfold compared to the general population. Radiologic extent was the most important prognostic factor.

Study context

Population
Adults (≥18 years) with rheumatoid arthritis (RA) resident in the Canterbury District Health Board (CDHB) catchment area, Canterbury, New Zealand, in 2006–2008 (Period One) and 2011–2013 (Period Two), followed until 30 June 2019
Outcome
Prevalence and incidence of RA-ILD; risk factors for development; outcomes (mortality)
Methodological detailspopulation-based, Cox proportional hazards models
  • Population-based
  • Cox proportional hazards models

Main finding

As reported in the abstract

Prevalence of RA-ILD per 100,000

Period One prevalence per 100,000

10.97

95% CI 7.53,14.42

Period Two prevalence per 100,000

14.74

95% CI 10.84,18.63

Cumulative incidence of ILD at 10 years

4.47 %

95% CI 3.14, 6.14

Observational data: associations, not effects.

Further findings

Risk factors for developing RA-ILD (age-adjusted)

HR (95 % CI)
RF positivityAdjusted for age3.73 (1.32,10.56)
Extra-articular manifestations other than RA-ILDAdjusted for age4.48 (2.36,8.48)
Subcutaneous rheumatoid nodulesAdjusted for age4.66 (2.34–9.26)
OutcomeHR (95 % CI)
Mortality by extent of ILD on CT chest>20%vs < 20 %4.47 (1.67,11.96)
OutcomeStandardised mortality ratio (95 % CI)
Mortality in RA-ILD vs general population3.90 (2.55,5.72)

Original publication

Rheumatoid interstitial lung disease in Canterbury, Aotearoa New Zealand – A retrospective cohort study. Semin Arthritis Rheum. Published 23 December 2023. doi:10.1016/j.semarthrit.2023.152359

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.